SCHEMBL7090740

SCHEMBL7090740

Cc1ccc(-c2ccccc2C(=O)C(=O)c2ccccc2)c(-c2ccc(F)cc2)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
CES2 O00748 6/20 0.39
CES1 P23141 6/20 0.39
MYC P01106 1/20 0.35
KDM4E B2RXH2 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
LMNA P02545 2/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ABL1 P00519 1/20 0.34
EIF4E P06730 1/20 0.34
TUBB4A P04350 2/20 0.33
TUBB P07437 2/20 0.33
TUBA3C P0DPH7 2/20 0.33
TUBA1B P68363 2/20 0.33
TUBA4A P68366 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7091359 0.87 PTGS2 (0.45) PTGS2
SCHEMBL7089420 0.84 SLC6A4 (0.39) SLC6A4SLC6A3CES2CES1KMT2A
SCHEMBL7085442 0.81 SLC6A4 (0.39) SLC6A4SLC6A3CES2CES1KMT2A
SCHEMBL7088115 0.78 SLC6A4 (0.42) SLC6A4SLC6A3CES2CES1KMT2A
SCHEMBL7085294 0.78 SLC6A4 (0.37) SLC6A4SLC6A3CES2CES1KDM4E
SCHEMBL981886 0.73 CES2 (0.52) CES2CES1MYCNPC1POLB
SCHEMBL7085149 0.73 PTGS2 (0.40) PTGS2
Ammonia Solution, Strong SCHEMBL27655386 0.73 CES2 (0.47) CES2CES1MYCKMT2AMEN1
SCHEMBL29972427 0.72 CES2 (0.67) CES2CES1LMNARAB9AALDH1A1
SCHEMBL7090744 0.72 SLC6A4 (0.41) SLC6A4SLC6A3CES2CES1MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 SLC6A4 2737/4885SLC6A3 3343/4885CES2 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.